Abstract
Health-related quality of life (HRQoL) is an important outcome in oncology care although an underexplored area in bladder cancer (BC). Our aims were to assess HRQoL of patients with BC, analyse relationships between diverse HRQoL measures and validate the Hungarian version of the Bladder Cancer Index (BCI) questionnaire. A cross-sectional survey was performed among patients with BC (N = 151). Validated Hungarian versions of the FACT-Bl, SF-36 and EQ-5D were applied and SF-6D was derived. Psychometric analysis of the Hungarian BCI was performed. Pearson correlations between the five measures were analysed. Deterioration in SF-36 Physical Functioning was detected among patients aged 45–64 years. The EQ-5D score did not differ significantly from the age-matched population norm. Correlations between the FACT-Bl, EQ-5D and SF-6D utility measures were strong (r > 0.6). Cronbach alpha coefficients of the Hungarian BCI ranged from 0.75 to 0.97 and factor analysis confirmed that data fit to the six predefined subdomains. Test-retest correlations (reliability, N = 50) ranged from 0.67 to 0.87 and interscale correlations between urinary, bowel and sexual BCI domains were weak or moderate (r = 0.29 to 0.49). Convergent validity revealed a stronger correlation with FACT-Bl (r = 0.126 to 0.719) than with generic health state scores (r = 0.096 to 0.584). Results of divergent validity of the Hungarian BCI by treatment groups by Kruskal Wallis test were promising although limited by low sample sizes in cystectomy subgroups. Generic health state measures have limited capacity to capture HRQoL impact of BC. Validity tests yielded favourable results for the Hungarian BCI. Mapping studies to estimate utility scores from FACT-Bl are encouraged but less recommendable with the BCI.
Similar content being viewed by others
References
Ploeg M, Aben KK, Kiemeney LA (2009) The present and future burden of urinary bladder cancer in the world. World J Urol 27(3):289–293. doi:10.1007/s00345-009-0383-3
Botteman MF, Pashos CL, Hauser RS, Laskin BL, Redaelli A (2003) Quality of life aspects of bladder cancer: a review of the literature. Qual Life Res 12(6):675–688
Ali AS, Hayes MC, Birch B, Dudderidge T, Somani BK (2014) Health related quality of life (HRQoL) after cystectomy: comparison between orthotopic neobladder and ileal conduit diversion. Eur J Surg Oncol. doi:10.1016/j.ejso.2014.05.006
Gilbert SM, Dunn RL, Hollenbeck BK, Montie JE, Lee CT, Wood DP, Wei JT (2010) Development and validation of the bladder cancer index: a comprehensive, disease specific measure of health related quality of life in patients with localized bladder cancer. J Urol 183(5):1764–1769. doi:10.1016/j.juro.2010.01.013
Hedgepeth RC, Gilbert SM, He C, Lee CT, Wood DP Jr (2010) Body image and bladder cancer specific quality of life in patients with ileal conduit and neobladder urinary diversions. Urology 76(3):671–675. doi:10.1016/j.urology.2010.01.087
Bartsch G, Daneshmand S, Skinner EC, Syan S, Skinner DG, Penson DF (2014) Urinary functional outcomes in female neobladder patients. World J Urol 32(1):221–228. doi:10.1007/s00345-013-1219-8
Poch MA, Stegemann AP, Rehman S, Sharif MA, Hussain A, Consiglio JD, Wilding GE, Guru KA (2014) Short-term patient reported health-related quality of life (HRQL) outcomes after robot-assisted radical cystectomy (RARC). BJU Int 113(2):260–265. doi:10.1111/bju.12162
Aboumohamed AA, Raza SJ, Al-Daghmin A, Tallman C, Creighton T, Crossley H, Dailey S, Khan A, Din R, Mehedint D, Wang K, Shi Y, Sharif M, Wilding G, Weizer A, Guru KA (2014) Health-related quality of life outcomes after robot-assisted and open radical cystectomy using a validated bladder-specific instrument: a multi-institutional study. Urology. doi:10.1016/j.urology.2014.02.024
Gaunez N, Larre S, Pires C, Dore B, Wei J, Pfister C, Irani J (2010) French translation and linguistic validation of the questionnaire bladder cancer index (BCI). Prog Urol 22(6):350–353. doi:10.1016/j.purol.2011.12.004
Schmidt S, Riel R, Frances A, Lorente Garin JA, Bonfill X, Martinez-Zapata MJ, Morales Suarez-Varela M, dela Cruz J, Emparanza JI, Sanchez MJ, Zamora J, Goni JM, Alonso J, Ferrer M (2014) Bladder cancer index: cross-cultural adaptation into Spanish and psychometric evaluation. Health Qual Life Outcomes 12:20. doi:10.1186/1477-7525-12-20
Yeung C, Dinh T, Lee J (2014) The health economics of bladder cancer: an updated review of the published literature. Pharmacoeconomics. doi:10.1007/s40273-014-0194-2
Torrance GW (1986) Measurement of health state utilities for economic appraisal. J Health Econ 5(1):1–30
Svatek RS, Hollenbeck BK, Holmang S, Lee R, Kim SP, Stenzl A, Lotan Y (2014) The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol. doi:10.1016/j.eururo.2014.01.006
McTaggart-Cowan H, Teckle P, Peacock S (2013) Mapping utilities from cancer-specific health-related quality of life instruments: a review of the literature. Expert Rev Pharmacoecon Outcomes Res 13(6):753–765. doi:10.1586/14737167.2013.850420
Tejido-Sanchez A, Garcia-Gonzalez L, Jimenez-Alcaide E, Arrebola-Pajares A, Medina-Polo J, Villacampa-Auba F, Diaz-Gonzalez R (2014) Quality of life in patients with ileal conduit cystectomy due to bladder cancer. Actas Urol Esp 38(2):90–95. doi:10.1016/j.acuro.2013.04.006
Li X, Fang Q, Ji H, Pan J, Zhang J, Li Z, Chen M, Wu X, Zhou Z, Chen Z (2014) Use of urostomy bags in the management of perioperative urine leakage after radical cystectomy. Cancer Nurs 37(3):170–174. doi:10.1097/NCC.0b013e318277db29
Kulkarni GS, Alibhai SM, Finelli A, Fleshner NE, Jewett MA, Lopushinsky SR, Bayoumi AM (2009) Cost-effectiveness analysis of immediate radical cystectomy versus intravesical bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. Cancer 115(23):5450–5459. doi:10.1002/cncr.24634
Wong KA, Zisengwe G, Athanasiou T, O’Brien T, Thomas K (2013) Outpatient laser ablation of non-muscle-invasive bladder cancer: is it safe, tolerable and cost-effective? BJU Int 112(5):561–567. doi:10.1111/bju.12216
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579
Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol group. Ann Med 33(5):337–343
McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD (1994) The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 32(1):40–66
Brazier J, Usherwood T, Harper R, Thomas K (1998) Deriving a preference-based single index from the UK SF-36 health survey. J Clin Epidemiol 51(11):1115–1128
Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, Bouter LM, de Vet HC (2007) Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 60(1):34–42. doi:10.1016/j.jclinepi.2006.03.012
Cohen J (1992) A power primer. Psychol Bull 112(1):155–159
Szende A, Nemeth R (2003) Health-related quality of life of the Hungarian population. Orv Hetil 144(34):1667–1674
Czimbalmos Á, Nagy Z, Varga Z, Hustik P (1999) Páciens megelégedettségi vizsgálat SF-36 kérdőívvel, a magyarországi normálértékek meghatározása. Népegészségügy 80(1):4–19
Sousa VD, Rojjanasrirat W (2011) Translation, adaptation and validation of instruments or scales for use in cross-cultural health care research: a clear and user-friendly guideline. J Eval Clin Pract 17(2):268–274. doi:10.1111/j.1365-2753.2010.01434.x
Acknowledgments
The study was supported by Foundation for Modern Urology (Pécs, Hungary), Centre for Public Affairs Studies Foundation and proofreading of the manuscript was supported by the TÁMOP 4.2.2. /B-10/1-2010-0023 project.
Conflict of Interest
Authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hevér, N.V., Péntek, M., Balló, A. et al. Health Related Quality of Life in Patients with Bladder Cancer: A Cross-Sectional Survey and Validation Study of the Hungarian Version of the Bladder Cancer Index. Pathol. Oncol. Res. 21, 619–627 (2015). https://doi.org/10.1007/s12253-014-9866-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12253-014-9866-7